AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36235821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) consumption with sucrose
Number of subjects: 0
Study 36235821 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SSB consumption)
Number of subjects: 0
Study 33624527 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 36
Study 33624527 — intervention group
Group type: COMPARATOR
Intervention: sham-ES
Number of subjects: 36
Study 35511720 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) at 60L/min
Number of subjects: 10
Study 35511720 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) at 40L/min
Number of subjects: 10
Study 35511720 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) at 4cmH2O
Number of subjects: 10
Study 33938977 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-piece, inflatable penile prosthesis in radial-free-flap phalloplasty
Number of subjects: 400
Study 33938977 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile prosthesis design for use in phalloplasties
Number of subjects: 400
Study 33938977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmen-specific penile prosthesis
Number of subjects: 400
Study 32781397 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention
Number of subjects: 103
Study 32781397 — intervention group
Group type: COMPARATOR
Intervention: Developmental Education for Families (DEF) control intervention
Number of subjects: 103
Study 36084050 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use
Number of subjects: 2086
Study 34640836 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Tape®
Number of subjects: 22
Study 34640836 — intervention group
Group type: COMPARATOR
Intervention: Kinesio tape
Number of subjects: 22
Study 32584519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion reaction learning module plus standard rotation training
Number of subjects: 55
Study 32584519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no module) receiving only standard training
Number of subjects: 55
Study 35287002 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfolding case-based learning
Number of subjects: 115
Study 35287002 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning methods
Number of subjects: 115
Study 33809557 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied formulation containing components of natural moisturizing factor (NMF)
Number of subjects: 12
Study 33809557 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 12
Study 32546652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the stroke trial
Number of subjects: 71
Study 32546652 — intervention group
Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the stroke trial
Number of subjects: 71
Study 32546652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the MS study
Number of subjects: 71
Study 32546652 — intervention group
Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the MS study
Number of subjects: 71
Study 32546652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined forecasts of neurology experts for the ALS study
Number of subjects: 71
Study 32546652 — intervention group
Group type: COMPARATOR
Intervention: Noncommittal prediction algorithm for the ALS study
Number of subjects: 71
Study 32546652 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual predictions by experts
Number of subjects: 71
Study 34278540 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAS‐r: Renal
Number of subjects: 506
Study 34278540 — intervention group
Group type: COMPARATOR
Intervention: EQ‐5D‐5L
Number of subjects: 506
Study 33493423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of an inhaled corticosteroid and a β‐agonist
Number of subjects: 600
Study 33493423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 32896919 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 0
Study 32896919 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 0
Study 36342940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation reimbursement ($5 USD) and up to three reminder phone calls for those not linking within seven days
Number of subjects: 199
Study 36342940 — intervention group
Group type: COMPARATOR
Intervention: Control group received a clinic referral only
Number of subjects: 199
Study 32315340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle and weight-loss intervention
Number of subjects: 0
Study 32315340 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 35573609 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 150
Study 35573609 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 150
Study 35573609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 33109455 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon pump (IABP)
Number of subjects: 690
Study 34057469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral skills (relaxation, cognitive restructuring, worry practice)
Number of subjects: 196
Study 34057469 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (health management content [HMC])
Number of subjects: 196
Study 34057469 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoaching (motivational interviewing)
Number of subjects: 196
Study 33432993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh group
Number of subjects: 93
Study 33432993 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol group (preserved at -78 °C)
Number of subjects: 93
Study 33432993 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS group (0.1% sodium dodecyl sulfate decellularization)
Number of subjects: 93
Study 33432993 — intervention group
Group type: COMPARATOR
Intervention: Glycerol group
Number of subjects: 93
Study 33432993 — intervention group
Group type: COMPARATOR
Intervention: SDS group
Number of subjects: 93
Study 35689478 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE
Number of subjects: 404
Study 35689478 — intervention group
Group type: COMPARATOR
Intervention: Community Care (CC)
Number of subjects: 404
Study 32861806 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg orally, once daily)
Number of subjects: 419
Study 32861806 — intervention group
Group type: COMPARATOR
Intervention: Platinum-pemetrexed (pemetrexed plus carboplatin/cisplatin, intravenously, every 3 weeks, ≤6 cycles)
Number of subjects: 419
Study 32861806 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (after crossover adjustment)
Number of subjects: 419
Study 32861806 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419
Study 32861806 — intervention group
Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 419
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 10 mg once daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 35 mg once daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg once daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 10 mg twice daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 25 mg twice daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib 100 mg twice daily
Number of subjects: 311
Study 36096203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 34738000 — intervention group
Group type: EXPERIMENTAL
Intervention: High sn-2 palmitic acid (OPO) formula
Number of subjects: 174
Study 34738000 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 174
Study 33044367 — intervention group
Group type: EXPERIMENTAL
Intervention: CUR + FEN (500 mg·d)
Number of subjects: 47
Study 33044367 — intervention group
Group type: EXPERIMENTAL
Intervention: FEN (300 mg·d)
Number of subjects: 47
Study 33044367 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 47
Study 33044367 — intervention group
Group type: EXPERIMENTAL
Intervention: CUR + FEN, FEN, PLA
Number of subjects: 47
Study 34715091 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel electrocardiogram algorithm
Number of subjects: 0
Study 34715091 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocardiogram algorithm
Number of subjects: 0
Study 33823421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-specialist telemedicine care
Number of subjects: 60
Study 33823421 — intervention group
Group type: COMPARATOR
Intervention: Usual territory care
Number of subjects: 60
Study 32293914 — intervention group
Group type: EXPERIMENTAL
Intervention: endobronchial induced pluripotent stem cell‐derived human MSCs (hMSCs) (n=7)
Number of subjects: 14
Study 32293914 — intervention group
Group type: COMPARATOR
Intervention: cell‐free carrier vehicle (vehicle control; n=7)
Number of subjects: 14
Study 33772303 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (GH) injections (0.050 mg/kg/day) for 12 months
Number of subjects: 14
Study 33772303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33772303 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (GH) injections
Number of subjects: 14
Study 33930115 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated nerve monitoring
Number of subjects: 200
Study 33930115 — intervention group
Group type: COMPARATOR
Intervention: Control (blinded monitoring)
Number of subjects: 200
Study 33930115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 34268601 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroids
Number of subjects: 0
Study 34268601 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 0
Study 34268601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial cancer
Number of subjects: 0
Study 34268601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 0
Study 32297923 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-down positioning
Number of subjects: 239
Study 32297923 — intervention group
Group type: COMPARATOR
Intervention: Support-the-break positioning
Number of subjects: 239
Study 35678744 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study 35678744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Volume High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 35678744 — intervention group
Group type: COMPARATOR
Intervention: Non-Exercising Control
Number of subjects: 28
Study 34972770 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) in a blended format (face-to-face individual UP + online, app-based UP)
Number of subjects: 310
Study 34972770 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (individual cognitive behavioural therapy)
Number of subjects: 310
Study 34972770 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) in a blended format
Number of subjects: 310
Study 35449368 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine plus standard triple antiemetic therapy (aprepitant, tropisetron, dexamethasone)
Number of subjects: 120
Study 35449368 — intervention group
Group type: COMPARATOR
Intervention: 5 mg olanzapine plus tropisetron and dexamethasone (omitting aprepitant)
Number of subjects: 120
Study 34127059 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at GB34
Number of subjects: 90
Study 34127059 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at EX‐LE6
Number of subjects: 90
Study 34127059 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-acupoint (Control)
Number of subjects: 90
Study 33355079 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (Group A): omeprazole, amoxicillin, clarithromycin, and bismuth subcitrate for 2 weeks.
Number of subjects: 160
Study 33355079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen (Group B): omeprazole and amoxicillin for 5 days, followed by omeprazole, tinidazole, and levofloxacin for 5 days.
Number of subjects: 160
Study 35186874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children for Teachers (ICC-T) intervention delivered as a 5-day training workshop
Number of subjects: 468
Study 35186874 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 468
Study 32460145 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cognitive rehabilitation (SCR)
Number of subjects: 35
Study 32460145 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific intervention (NSI)
Number of subjects: 35
Study 33925694 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop (WS) version of SUCCEAT
Number of subjects: 0
Study 33925694 — intervention group
Group type: EXPERIMENTAL
Intervention: Online (ONL) version of SUCCEAT
Number of subjects: 0
Study 33925694 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop (WS) and Online (ONL) versions of SUCCEAT
Number of subjects: 0
Study 32435820 — intervention group
Group type: EXPERIMENTAL
Intervention: extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 0
Study 32435820 — intervention group
Group type: COMPARATOR
Intervention: standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study 34935724 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of damask rose 40% and lavender 10% essential oils
Number of subjects: 62
Study 34935724 — intervention group
Group type: COMPARATOR
Intervention: Routine dressing protocol
Number of subjects: 62
Study 32744426 — intervention group
Group type: COMPARATOR
Intervention: Multimedia psychosocial intervention (MPI)
Number of subjects: 103
Study 32744426 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial information package (PIP)
Number of subjects: 103
Study 32744426 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study 36196601 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium (900 mg)
Number of subjects: 48
Study 36196601 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 48
Study 36196601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33121289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/d melatonin
Number of subjects: 51
Study 33121289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/d melatonin plus 30 minutes of 10,000 lux bright light therapy (BLT)
Number of subjects: 51
Study 33121289 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/d placebo
Number of subjects: 51
Study 32118274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (death caused by VL)
Number of subjects: 360
Study 32118274 — intervention group
Group type: COMPARATOR
Intervention: Controls (cured)
Number of subjects: 360
Study 33601849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Toxoplasma antibodies (IgG) testing
Number of subjects: 500
Study 33601849 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Toxoplasma antibodies (IgM) testing
Number of subjects: 500
Study 33601849 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR testing for T. gondii DNA
Number of subjects: 500
Study 33601849 — intervention group
Group type: EXPERIMENTAL
Intervention: Avidity test for IgG antibodies
Number of subjects: 500
Study 33601849 — intervention group
Group type: COMPARATOR
Intervention: Seropositivity rate comparison
Number of subjects: 500
Study 34849690 — intervention group
Group type: EXPERIMENTAL
Intervention: Local gentamicin treatment (collagenous carriers containing gentamicin left between sternal halves during sternal refixation)
Number of subjects: 41
Study 34849690 — intervention group
Group type: EXPERIMENTAL
Intervention: Local gentamicin treatment
Number of subjects: 41
Study 34849690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local antibiotics used)
Number of subjects: 41
Study 34849690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 33198568 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks + conventional therapy)
Number of subjects: 26
Study 33198568 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 26
Study 34506343 — intervention group
Group type: EXPERIMENTAL
Intervention: ART provided three‐monthly in community ART groups (3MC)
Number of subjects: 10136
Study 34506343 — intervention group
Group type: EXPERIMENTAL
Intervention: ART provided 6‐monthly in either CAGs or on an individual provider‐patient basis (6MC)
Number of subjects: 10136
Study 34506343 — intervention group
Group type: EXPERIMENTAL
Intervention: ART provided three‐monthly in community ART groups (3MC) and ART provided 6‐monthly (6MC)
Number of subjects: 10136
Study 34506343 — intervention group
Group type: COMPARATOR
Intervention: ART collected 3‐monthly at healthcare facilities (3MF)
Number of subjects: 10136
Study 36429807 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention for 12 weeks
Number of subjects: 30
Study 36429807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 33772131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99
Study 33772131 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 99
Study 32658385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy (15 minutes twice daily using a cough assist device over 12 months)
Number of subjects: 34
Study 32658385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsufflation therapy
Number of subjects: 34
Study 32658385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 34151671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) from the first day of the cycle to five days before starting ovarian stimulation
Number of subjects: 86
Study 34151671 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/12 hours of oral E2 valerate from day 25 of the previous cycle until the day before starting stimulation
Number of subjects: 86
Study 34151671 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 86
Study 34496087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanomicelle curcumin (CUR) 80 mg
Number of subjects: 120
Study 34496087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (NS) 1,000 mg
Number of subjects: 120
Study 34496087 — intervention group
Group type: EXPERIMENTAL
Intervention: CUR (80 mg) and NS (1,000 mg)
Number of subjects: 120
Study 34496087 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 120
Study 34497110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (pooled doses)
Number of subjects: 8246
Study 34497110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study 32780926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg over 10 minutes, 0.5 µg/kg/h during surgery, and 1 µg/kg after cardiopulmonary bypass)
Number of subjects: 141
Study 32780926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 141
Study 32780926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 141
Study 36344766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg oral nanocrystal formulation for 10 days
Number of subjects: 701
Study 36344766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 36344766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 701
Study 34880976 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat platform health management and continuous refined nursing
Number of subjects: 100
Study 34880976 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing after PCI
Number of subjects: 100
Study 35986308 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral designs encouraging savings behavior through SMS text messages plus standard Mama Program offering
Number of subjects: 700
Study 35986308 — intervention group
Group type: COMPARATOR
Intervention: Standard Mama Program offering
Number of subjects: 700
Study 33795622 — intervention group
Group type: EXPERIMENTAL
Intervention: ColoWrap
Number of subjects: 350
Study 33795622 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 350
Study 32652024 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/d of MCTs (MCT group)
Number of subjects: 64
Study 32652024 — intervention group
Group type: COMPARATOR
Intervention: 6 g/d of long-chain triglycerides (LCT group)
Number of subjects: 64
Study 32652024 — intervention group
Group type: COMPARATOR
Intervention: LD + MCT group (1.2 g L-leucine and 20 μg cholecalciferol enriched with 6 g/d of MCTs)
Number of subjects: 64
Study 35906491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty
Number of subjects: 230
Study 35906491 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 230
Study 32520897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio
Number of subjects: 680
Study 32520897 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma/PRBC and high platelet/PRBC ratios
Number of subjects: 680
Study 32520897 — intervention group
Group type: COMPARATOR
Intervention: Low transfusion ratios of plasma and platelets
Number of subjects: 680
Study 32520897 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual transfusion ratios received
Number of subjects: 680
Study 35078831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix graft (ADMG) combined with coronally advanced flap (CAF)
Number of subjects: 40